Evaluation of new adjuvants in enhancing the immune response to a candidate of Severe Fever with Thrombocytopenia Syndrome Virus vaccine.

Severe fever with thrombocytopenia syndrome (SFTS) is a viral disease transmitted by ticks that can cause severe illness. Currently, there are no licensed treatments. Researchers evaluated a vaccine candidate based on a specific strain of the virus. This adjuvanted vaccine was tested in mice. The research looked at how different adjuvants influenced the immune response.

Addavax and another adjuvant called SDI were found to be most effective in boosting antibody production. The vaccine's main target was the virus's nucleoprotein, which triggered a broad immune response. Other parts of the virus, like a protein called Gn, induced weaker immune responses. Importantly, sera from mice immunized with SDI or Addavax showed cross-reactivity with a different strain, indicating broader protection.

The vaccine also provided partial protection when transferred to other mice. These results suggest that the vaccine platform holds promise and that adjuvant choice plays a crucial role in determining the effectiveness and breadth of the immune response.